![]() Carrick Therapeutics Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments. | ![]() Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. | Kyowa Kirin Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. | |||
Founding Date | Founding Date 2015 | Founding Date 1781 | Founding Date 2000 | Founding Date 1978 | Founding Date 2008 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Dublin, IE HQ Oxford, GB | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations Bengaluru, IN HQ Bengaluru, IN Nanakramguda, IN Dublin, IE Kuala Lumpur, MY Puchong, MY Delémont, CH see more | ||
Employees | Employees 17 | Employees 47,4554% decrease | Employees 82517% decrease | Employees 16,5612% increase | Employees 5,669 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 43.7 b | Valuation ($) 648.3 m | Valuation ($) N/A | Valuation ($) 8.8 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ¥4.6t (FY, 2025) | Revenue (est.) €535.2m (FY, 2024) | Revenue (est.) ₹167.8b (FY, 2026) | Revenue (est.) ¥496.8b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods ¥818.8b (FY, 2025) | Cost of goods €9.7m (FY, 2024) | Cost of goods ₹56.9b (FY, 2026) | Cost of goods ¥114.3b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit ¥3.8t (FY, 2025) | Gross profit €534.4m (FY, 2024) | Gross profit ₹115.8b (FY, 2026) | Gross profit ¥383.4b (FY, 2025) |
Net income | Net income N/A | Net income ¥108.1b (FY, 2025) | Net income €162.2m (FY, 2024) | Net income ₹3.7b (FY, 2026) | Net income ¥67b (FY, 2025) |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 2 (May, 2025) | Phase I Trials Products 3 (May, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 95m | Total funding raised $ 57.8m | Total funding raised $ 1.1b | Total funding raised N/A | Total funding raised N/A |

Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View company
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View company
Biocon is a company that develops and manufactures biopharmaceutical products.
View companyKyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.
View company